INTRODUCTION
Despite extensive study, the basic immune mechanism(s) causing lupus remains unknown. The murine chronic graft-versu+host model demonstrates that alloreactive CD4+ T cells responding to host class 11 MHC molecules in \*i~o can produce a disease resembling systemic lupus erythematosus (SLE) ( I. 3). leading some authors to speculate that autoreactive CD4 + cells with class II specificity may cause human SLE by a similar mechanism (3) . These autoreactive cells have been sought in SLE patients using the autologous mixed lymphocyte reaction (AMLR), with largely negative results (4) (5) (6) (7) . Despite this, the concept that autoreactive T cells cause SLE remains attractive since autoreactive cells may be distributed in locations other than peripheral venous blood. such as lymphatic tissue. or the autoreactive cells may be refractory to restimulation in ~*itro (81, preventing their detection.
Our group has found indirect evidence that autoreactive T cells may be involved in the pathogenesis of human SLE. We have reported that cloned antigen-specific T cells can become autoreactive following treatment with the DNA methylation inhibitor 5-azacytidine (5azaC) (9) . Procainamide, which induces a SLE-like syndrome in some patients, also induces autoreactivity in cloned 7' cells and inhibits DNA methylation (IO, 11) . Furthermore, patients with active idiopathic SLE have recently been found to have hypomethylated T cell DNA (12) . These results suggest an association between DNA hypomethylation, T cell autoreactivity, and SLE. and provide a model in which DNA hypomethylation predisposes to T cell autoreactivity, possibly by modifying gene expression, and the autoreactive 'I cells participate in the pathogenesis of the autoimmune disease. However. the functional consequences of 5-azaC-induced T cell autoreactivity have not been defined.
The cellular immune abnormalities characterizing SLE include peripheral venous B cells actively secreting immunoglobulin and T cells bearing activation markers (13) (14) (15) (16) . The autoreactive and chronic graft-versus-host models provide an explanation for the T cell activation since in both models T cells could be activated by class II MHC determinants on B cells, macrophages, or other class II bearing cells. The murine chronic graft-versus-host disease model also predicts that autoreactive T cells should be able to induce autologous B cells to differentiate into immunoglobulin-secreting cells, some secreting autoantibodies (2, 17) . We now report testing the autoreactive model by treating interleukin (IL)-2-dependent CD4+ T cell lines with DNA methylation inhibitors, then asking whether the treated cells cause autologous B cells to differentiate into immunoglobulin-secreting cells.
MATERIALS AND METHODS

T Cell Lines
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation as described (9) . To obtain CD4+ and CD8+ subsets, 20 x lo6 freshly isolated PBMC were suspended in 0.5 ml RPM1 1640 and 5 pg OKT4 or OKT8 (Ortho Pharmaceuticals, Raritan, NJ) was added. The cells and monoclonal antibodies (mAb) were incubated at 4°C 15 min prior to the addition of 0.5 ml rabbit complement (Pel-Freeze, Brown Deer, WI). The mixture was incubated at 37°C for 45 min, the cells were then washed twice in HBSS (GIBCO, Grand Island, NY). This treatment was repeated once. T cells were activated with 0.5-1.0 kg/ml phytohemagglutinin (PHA) (Burroughs Wellcome, Greenville, NC) in RPM1 1640 containing 10% fetal calf serum (FCS) (HyClone, Logan, UT), 100 U/ml penicillin, and 100 kg/ml streptomycin, and expanded in the same media supplemented with IL-2 (conditioned media from MLA-144 cells) (18) . Lines were cultured .in 24-well plates (Nunc, from GIBCO) and were restimulated weekly by adding lo6 irradiated (2OOOR) autologous PBMC to serve as APC plus 10 r&ml OKT3 (Ortho Pharmaceuticals).
Fresh IL-2 was added twice weekly.
.Pharmacologic Modification of T Cells 5-azaC, hydroxyurea, procainamide (all from Sigma Chemical Co., St. Louis, MO), and N-acetylprocainamide (Napa) (Aldritch Chemical Co., Milwaukee, WI) were added to proliferating T cells, and 6-8 days later the cells were washed and used for flow cytometry, proliferation, or B cell differentiation assays.
Flow Cytometric Analysis
Fluorescein conjugates of anti-CD4, anti-CD8, anti-2H4, and anti-4B4 were purchased from Coulter (Hialeah, FL). Cells were stained with these reagents and analyzed on an EPICS V flow cytometer as previously described (19).
Proliferation Assay T cell proliferation was determined by tritiated thymidine ([3H]TdR) incorporation as previously described (9) (10) (11) . Briefly, T cells were washed free of IL-2 and were cultured 16 hr in RPMI/lO% FCS. T cells (2 x 104) were then cultured with 10' freshly isolated autologous irradiated (2000 R) PBMC in 200 ~1 of RPMI/lO% FCS. Two days later, 0.5 &i of 13H]TdR (New England Nuclear, Boston, MA) was added to each well, and 18 hr later the cells were harvested and 3H incorpora io t n into DNA was determined. All assays were performed in quadruplicate. In some experiments T cells were not precultured in the absence of IL-2. In these experiments, proliferation was measured 3 days after setting up the assay. No significant differences were observed between the two methods.
B Cell Differentiation Assay
All studies were performed with autologous B cells. B cells were isolated from PBMC by depletion of adherent and rosette-forming cells as previously described and are routinely >95% Ig+ (20). For assay, IL-2-dependent T cell lines were washed free of IL-2 and cultured in RPMI/lO% FCS for 1-2 days. T cells (5 x 104) were then cultured with 1.25 x lo4 freshly isolated autologous B cells in flatbottomed microtiter wells containing 0.2 ml RPMI/lO% FCS. All cultures were performed in quadruplicate. The cultures were fed with an additional SO p,I of RPMI/IO% FCS on Days 4 and 8, and on Day 10 the supernatants were harvested and stored at -20°C until assayed for immunoglobulin.
Antibody Assays
IgG and IgM in culture supernatants were measured by ELISA as described previously (20). The radioimmunoassay for anti-DNA antibodies was performed as previously published (21) , and the radioimmunoassay for anti-histone antibody assay was performed according to the method of Rubin et al. (22) . The ELISA for antilymphocyte antibodies was performed by washing CD4 + , IL-2-dependent T cells, then pipetting 5 x lo5 cells into flat-bottom 96-well Immulon plates (Nunc, from GIBCO). The plates were centrifuged at 100~ for 5 min, the media discarded. and the cells fixed with 1% glutaraldehyde in 0.01 M PO,, pH 7.4, 0.9% NaCl (PBS) for 15 min at 25°C. After three washes with PBS the wells were filled with 100 ~1 of 2% bovine serum albumin (BSA) (Sigma) in PBS for 1 hr, then antibody containing supernatants or serial dilutions of anti-CD2 mAb (Ortho Pharmaceuticals, Raritan, NJ) were added in 2% BSA/PBS and incubated at 4°C overnight, The plates were washed with PBS again, then 80 ~1 protein A-alkaline phosphatase (Sigma) diluted 1:500 in 0.234 M Tris, pH 8.0,O. 1 pM MgCl,, 3 pM NaN,, 1% hen egg albumin (Sigma) was added for 1 hr. After three washes, 100 pJ phosphatase substrate (Sigma) was added at 1 mg/ml in 0.025 M carbonate buffer, pH 9.8, and the plates were incubated at 37°C until a color change was apparent. The plates were read at 405 nm on a Titertek Multiskan ELISA plate reader.
Monoclonal Antibodies
The anti-class I mAb, specific for nonpolymorphic MHC determinants, was purchased from Cappel Laboratories (Cochranville, PA). The anti-class II mAb, 9.49 (23) , and the control NS-I ascites were a generous gift from Dr. Robert Todd, III.
Statistical Analysis
The difference between means was compared using Student's t test and all experiments were repeated two to five times. Polyclonal T cells were chosen for these studies, rather than cloned tetanus toxoid reactive cells, to more closely approximate in viva immune responses. We first established that SazaC-treated polyclonal T cells could respond to autologous PBMC. Interleukin-2-dependent, proliferating, polyclonal CD4 + and CD8 + cell lines were treated with 1 pJ4 S-azaC for 6-8 days, then challenged with irradiated (2000 R) autologous PBMC. The optimal concentration for inducing autoreactivity was previously shown to be 1 FM 5-azaC (9). Proliferation was measured 3 days later by [3H]TdR incorporation.
The results of two experiments are shown in Table 1 . A small proliferative response to irradiated PBMCs was observed in all lines and presumably represents the AMLR. 5-azaC treatment markedly increased the proliferative response of CD4 + but not CD8 + cells to autologous PBMC. The proliferative response to anti-CD3 mAbs was used as a positive control in these experiments, and within each experiment the response to anti-CD3 was not significantly different among the lines.
To test whether class II MHC determinants were required for the CD4+ response, activation of treated CD4+ cells by irradiated autologous APC was inhibited with varying amounts of mAb to class I or class II determinants or a control murine ascites (Fig. 1 ). Anti-class II mAbs were found to abrogate the response, while similar concentrations of control ascites did not, and mAb to class I determinants in concentrations as high as 100 rig/ml did not significantly inhibit. Since 5-azaC did not alter CD8+ reactivity, we asked whether CD4+-cells could provide help for an autologous response by CD8+ cells. 5-azaC-treated CD4 and CD8 cells were mixed in variable ratios and were then challenged with irradiated autologous PBMC (Fig. 2) . CD8 + cells decreased the CD4 response to PBMC, but did not augment or diminish the response beyond that expected by diluting the CD4 + cells. In these experiments, anti-CD3-induced proliferation was used again as a positive control, and the response to anti-CD3 was similar among the lines. Identical results were observed mixing untreated IL-2-dependent CD8 + cells with 5-azaC-treated CD4 + cells.
Effect of S-azaC on 2H4 (CD45R) and 484 (CDw29) Expressiorl
The response of 5-azaC-treated CD4 + cells to autologous PBMC resembles the AMLR, which is also a T cell response to autologous non-T cells without added antigen (24) . Recent reports indicate that AMLR responsive cells are mainly found in the CD4+ 2H4 + subset (25) . To test whether 5-azaC selects for the 2H4+ subset, the CD4+ line was treated with 0.25-2.0 $V 5-azaC and 6 days later was tested for 2H4 and 4B4 expression by flow cytometric analysis (Fig. 3) . Six days was previously shown to be the optimal time to detect 5-azaC-induced changes in T cells (19). The untreated CD4 + line was primarily 2H4 -. 5-azaC caused a small dose-dependent decrease in 4B4 expression, but did not increase 2H4 expression. To test whether CD4+ and CD8+ cells treated with DNA methylation inhibitors induced autologous B cell differentiation, CD4+ and CD8+ lines were treated with 0.25-2.0 pM 5-azaC, and 6 days later the cells were cultured for an additional 2 days without IL-2, then cultured with freshly isolated autologous B cells without added antigen or mitogen. Ten days later the supernatants were harvested and secreted IgG was measured by ELISA (Fig. 4) . Untreated CD4+ cells induced secretion of approximately 19 &ml IgG. In contrast, CD4-t cells treated with 1 pM 5-azaC induced secretion of 565 rig/ml IgG. Treated CD8 + cells did not induce significant IgG secretion. To exclude the possibility that the IgG measured reflected B cell lysis and release of presynthesized IgG rather than B cell activation, B cells were frozen and thawed and released IgG was measured. Under conditions similar to those of the culture system, lysed B cells released 4.9 + 0.4 rig/ml IgG.
To examine whether B cell differentiation required direct T-B contact or could be mediated via secreted lymphokines, IL-Zdependent CD4-t cells treated with 1 pM 5-azaC and untreated control lines were washed free of IL-2 and were cultured in RPM1 containing 10% FCS but no IL-2. Two days later the cells were removed by centrifugation and 0.2 ml of the lymphokine-enriched supematants was added to 5 x lo4 freshly isolated autologous B cells in microtiter wells. Ten days later the supernatants were recovered and secreted IgG was measured by ELISA as before (Table 2 ). B cells cultured with media alone secreted less than 15 rig/ml IgG, and the T cell supernatants also contained less than 15 r&ml IgG. Table 1 . In these experiments, [3H]TdR incorporation by treated and untreated CD4 cells cultured alone was less than 1700 cpm. These results suggested that 5-azaC treatment could make the T cells respond to autologous B cells and secrete lymphokines.
Alternatively, 5-azaC treatment could cause prolonged lymphokine secretion, producing the B cell differentiation observed in coculture experiments. This possibility was examined by treating CD4 + cells with 1 piU 5-azaC, and 6 days later the cells were washed free of IL-2. Treated and untreated cells were resuspended in RPMI/lO% FCS and supematants were collected between 0 and 12, 12 and 24, 24 and 36, and 36 and 48 hr after removal of IL-2. The supernatants were then added to cultured autologous B cells as before, and 10 days later secreted IgG was measured. Supematants from treated and untreated cells collected O-12 hr after removal of IL-2 produced B cell differentiation, while supernatants collected at later times did not. These results indicate that 5-azaC treatment does not result in prolonged lymphokine secretion.
We next compared the effect of other DNA methylation inhibitors on T cells using the B cell differentiation assay. Table 3 summarizes the results of experi- " CD4 cells were treated with 0.5-2.0 pM 5-azaC, 10 pM hydroxyurea. 10 uM procainamide, 10 uh4 Napa, or left untreated t-), then cultured with autologous B cells as described in Fig. 4 .
' Results represent the means -t SEM of the IgG response of three independent experiments, each performed in quadruplicate, comparing 0.5-2.0 pM 5-azaC and 10 PM hydroxyurea with untreated cells, and live experiments comparing 10 (LM procainamide and IO (*M Napa.
' Results of 5-azaC-and hydroxyurea-treated cells were compared to those obtained with untreated cells and results from procainamide-treated cells were compared to those from Napa-treated cells. P values were determined using Student's f test. N.S.. not significant. ments comparing B cell differentiation induced by SazaC, procainamide, Napa, hydroxyurea, and untreated CD4+ cells. Hydroxyurea is a DNA synthesis inhibitor that does not inhibit DNA methylation (26) , and procainamide is a more potent inducer of T cell autoreactivity than Napa (1 I). CD4 + cells were treated with 0.5-2.0 pM SazaC, 10 pM hydroxyurea, 10 FM procainamide, or 10 pM Napa, then cultured with autologous B cells as before. The highest concentration in which IL-2-dependent cells can survive was previously shown to be 10 pM hydroxyurea (19), and 10 pM procainamide induces autoreactivity while 10 pM Napa does not (11) . SazaC-and procainamide-treated CD4 + cells, but not hydroxyurea-or Napa-treated or untreated CD4+ cells, induced significant B cell differentiation, as evidenced by IgG secretion. Since procainamide induces antilymphocyte (27) and antinuclear antibodies (28) in viva, we tested whether IgG induced by 5-azaC-and procainamide-treated CD4 + cells contained similar autoantibodies. IgG containing supernatants from B cells activated by procainamide-and 5-azaC-treated T cells were tested for anti-DNA antibodies using a radioimmunoassay which detected 0.1 rig/ml of anti-DNA antibodies in control antisera and none were detected. Antihistone antibodies were sought using a radioimmunoassay which detected 0.5 rig/ml control antihistone antibody, and no antihistone antibodies were detected in the B cell supernatants. Finally, antilymphocyte antibodies were sought using a protein A-ELISA technique capable of detecting 1 rig/ml of anti-CD2, using the CD4 + line as target, and no antilymphocyte antibodies were detected (data not shown). All studies were performed using supernatants containing 300-1000 rig/ml IgG.
In all the studies presented IgM was also measured. While 5-azaC-treated CD4 + cells also induced IgM secretion, the magnitude of the IgM response varied widely between experiments, possibly reflecting donor effects (data not shown). lines respond to autologous PBMC, and that CD4 + cells treated with DNA methylation inhibitors induce differentiation in autologous B cells without the addition of mitogen or specific antigen. Untreated CD4 + and CD8 + lines demonstrated a small proliferative response to autologous irradiated PBMC, which presumably is the autologous mixed lymphocyte reaction (24) . 5-azaC treatment markedly augmented this response in CD4+ lines, but did not alter the CDS+ response. Mixing studies using treated CD4 and CD8 + cells demonstrated that the failure of CD8 + cells to respond to autologous PBMC was not due to a lack of CD4 + cells. The CD8 + cells did not suppress the CD4 response, probably due to difficulties in maintaining suppressor cells in long term lines (29) . The CD4 + response was inhibited with monoclonal antibodies to class II but not class I MHC determinants, suggesting that the cells could be responding to autologous HLA-D determinants on the PBMCs. These results are similar to previously published experiments in which SazaC-treated, cloned tetanus toxoid-specific CD4 + T cells lost the requirement for antigen and could be activated by autologous class II determinants alone (9), while 5-azaC-treated, cloned CD8+ antigen-specific cells did not demonstrate a similar altered reactivity (19). It is reasonable to propose that 5-azaC is inducing autoreactivity in the polyclonal CD4 + lines by the same mechanism that autoreactivity is induced in cloned lines. In other experiments using 5-azaC-treated cloned CD4 + cells, the autoreactive response was inhibited with mAb to CD2, CD1 la, and ICAM-I, but not CD4 (30), suggesting that molecules of the integrin family are also involved in this response.
Alternatively, in these experiments, 5-azaC treatment may select for AMLR responsive cells in polyclonal lines. Recent reports indicate that AMLR responsive cells are primarily found in the CD4 + 2H4 + population (25) . Therefore, we tested whether 5-azaC altered the percentage of 2H4+ (CD45R) and 4B4+ (CDw29) cells in the polyclonal lines. The untreated lines contained mostly 2H4-cells. The low percentage of 2H4 + cells in the untreated lines probably represents loss of the 2H4 determinant in these IL-2-dependent lines (31). 5-azaC treatment did not increase the percentage of 2H4+ cells, indicating that 5-azaC is not selecting this T cell subset. Interestingly, CD4 + 2H4 + cells are also diminished in the peripheral blood of SLE patients (32) . Furthermore, other investigators have reported that CD4+ AMLR responsive cells provide help to AMLR responsive CD8 + cells (33, 34) . This is not the case in this system, also arguing against a selection for AMLR responsive cells.
While the mechanism by which 5-azaC alters the activation requirements of CD4+ cells remains uneertain, the response appears to have functional significance since 5-azaC-treated CD4 + cells reproducibly induced differentiation in autologous B cells without the addition of exogenous antigen or mitogen. Hydroxyurea-treated CD4+ cells failed to induce B cell differentiation, consistent with previous observations that hydroxyurea does not induce autoreactivity in cloned CD4 + cells (9) . T cells treated with 10 TV& procainamide also activated B cells, but T cells treated with 10 l& Napa did not. The procainamide-treated cells presumably induced B cell differentiation via a mechanism similar to 5-azaC since cloned T cells treated with 10 FM procainamide become autoreactive, while cells RICHARDSON, LIEBLING. AND HUDSON treated with 10 t~,fr4 Napa do not (11) . Significantly, this procainamide concentration is close to that achieved therapeutically in vivo (35) and may play a role in the B cell activation found in patients with active procainamide-induced SLE (13) . DNA methylation inhibitors administered in viva could also theoretically directly induce B cell differentiation.
However, we have treated the B cell line RPM1 4265 as well as Epstein-Barr transformed B cells with 5-azaC and found no change in IgG or IgM secretion or in expression of surface Ig (unreported observations). This suggests that a direct effect of DNA methylation inhibitors on B cells is unlikely to be a mechanism responsible for B cell activation.
Supernatants This is supported by experiments demonstrating that 5-azaC-treated CD4 + cells proliferate when challenged with autologous B cells. Since T cells from patients with idiopathic SLE appear to have hypomethylated DNA, this model may also apply to idiopathic SLE. Other authors have reported isolating autoreactive, Ia-specific T cell lines which also induce B cell differentiation via secreted lymphokines (39, 40) , supporting this model. The relationship of these naturally occurring autoreactive cells to 5-azaC-treated cells remains to be determined.
Procainamide-induced and idiopathic SLE are also characterized by anti-DNA, antihistone, and antilymphocyte antibodies (27, 28, 41) . These were sought in supernatants from B cells activated by 5-azaC-and procainamide-treated T cells and none were found. If autoantibodies were synthesized, they were present in amounts too small to detect. The assays could detect nanogram amounts of autoantibodies, and the supernatants contained more than 100 rig/ml of IgG, indicating that any autoantibodies would account for less than 1% of the secreted IgG. However, the B cell donor in these experiments was a healthy volunteer without risk factors for autoimmune disease. In patients with autoimmune diseases or receiving procainamide, in vivo priming to nuclear antigens could occur (42, 43) . Exposure to self-antigens in vivo, together with lymphokines supporting B cell differentiation, could enrich for autoantibody-secreting B cells in patients with SLE. It will be important to repeat these studies in patients with autoimmune diseases and controls to test this hypothesis. Furthermore, precursor frequency analysis for autoantibodies in idiopathic SLE indicates that B cells making anti-DNA antibodies are present at approximately 0.36 per lo6 PBMC (44) , while there are approximately 4000 Ig-secreting cells/IO6 PBMC in similar patients (45) , suggesting that precursors for anti-DNA antibodies make up only a small fraction of the Ig made in active SLE. This could also explain the low level of autoantibodies found in this system.
